1748P 4-factor model to predict response and survival benefit with durvalumab (D) in previously treated metastatic urinary tract carcinoma (mUTC)
Sonpavde, G.P., Sternberg, C.N., Lee, J-L., Emeribe, U., Oh, S.M., Dantas De Lima, A.R., Hotte, S.J.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article